FIND

The Swiss Malaria Group members are operating in almost all malaria endemic countries. With their commitment they are contributing to the global fight against malaria. For more information on our members, please go to the member's website by clicking on the member's logo.

Development of a serological rapid test for risk of P. vivax relapse

A host antibody marker of past P. vivax infection is targeted in a lateral flow assay in development by Mologic (UK). Clinical studies with partners in Indonesia and Australia will evaluate the assay performance in two longitudinal cohort studies monitoring P. vivax clinical exposure and relapse events.

Länder

indonesia united-kingdom japan australia

Auswirkung

1,180 persons

Dauer

2015 - ongoing

Aktivität

Innovation,Diagnosis